The HERG Screening Market is witnessing significant growth, propelled by the increasing demand for cardiotoxicity assessment in drug development and safety testing. Cardiotoxicity assessment, particularly focused on evaluating the risk of drug-induced cardiac arrhythmias, is a crucial step in the drug development process. HERG (human ether-a-go-go-related gene) screening plays a pivotal role in this assessment by evaluating the potential of drugs to block the hERG potassium ion channel, which is known to be associated with drug-induced QT prolongation and torsades de pointes arrhythmias. Through high-throughput screening techniques and advanced electrophysiological assays, HERG screening enables pharmaceutical companies and researchers to identify and mitigate cardiotoxic effects early in the drug development process, thereby improving patient safety and reducing the risk of adverse cardiac events associated with new medications.

The size of the HERG Screening Market was estimated at USD 0.9 billion in 2022. The market for HERG screening is anticipated to increase from USD 1.0 billion in 2023 to USD 2.6 billion by 2032, with a compound annual growth rate (CAGR) of 12.50% over the course of the forecast period (2023-2032).

Segment Analysis

• Type Segmentation: The global HERG screening market is segmented into gene KCNH2 and mutant KCNH2. KCNH2 gene, responsible for potassium channel production, dominates the market.
• Ion Channel Classification: Based on ion channels, the market is categorized into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage-gated ion channel holds the largest market share, while ion-gated channel exhibits the fastest growth.
• Application Division: Segments include antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug segment is anticipated to hold a significant market share.

Regional Analysis

• Americas: Divided into North America and Latin America, with the former further segmented into the US and Canada. The Americas lead the HERG screening market, driven by technological advancements and high cardiac disease prevalence.
• Europe: Separated into Western Europe and Eastern Europe, with the former including major countries like Germany, France, the UK, Italy, Spain, and others. Players in these regions focus on new launches and acquisitions.
• Asia-Pacific: Comprising China, India, Japan, South Korea, Australia, and others. Growth is fueled by a large patient pool with cardiac disorders and the demand for drug development.
• Middle East Africa: Subdivided into the Middle East and Africa, contributing to the global HERG screening market with their unique market dynamics and growth factors.

Within the realm of cardiac safety pharmacology, ion channel blockade assessment is a key component of cardiotoxicity evaluation, contributing to the broader HERG Screening Market. Ion channel blockade refers to the inhibition or modulation of ion channels, such as potassium, sodium, and calcium channels, which play crucial roles in cardiac electrophysiology. Drugs that block these ion channels may disrupt normal cardiac repolarization, leading to potentially life-threatening arrhythmias. Through in vitro and in vivo assays, ion channel blockade assessment evaluates the effects of drugs on cardiac ion channels, including HERG channels, to predict their proarrhythmic potential. By incorporating ion channel blockade assessment into preclinical safety testing protocols, pharmaceutical companies can assess the cardiac safety profiles of candidate compounds more comprehensively, facilitating informed decision-making and regulatory approval processes within the HERG Screening Market.

Key Players

MRFR recognizes the following HERG Screening companies as the top key players in global industry —Thermo Fisher Scientific, Eurofins Discover X Corporation, Charles River Laboratories, Merck KGaA, Metrion Biosciences Ltd, and Aurora Biomed, Inc.

Key Findings of the Study

• HERG Screening Market is expected to register a CAGR of 12.50% during the assessment period of 2023 to 2032.
• The Americas accounted for the largest share of the global HERG screening market due to the presence of prominent players in the US, high uptake rate, and product clearances from regulatory authorities.
• Based on type, the KCNH2 gene segment accounted for the largest market share.
• On the basis of ion channel, the voltage-gated ion channel segment is expected to be the fastest-growing segment during the forecast period.
• Based on application, the antiarrhythmic drug segment is expected to be the largest and fastest-growing segment during the forecast period.

For more information visit at MarketResearchFuture

Other Trending Reports

Healthcare cold chain logistics

Hemorrhoids Treatment

Plasma Fractionation

Aesthetics